Arcutis Biotherapeutics, Inc. 是一家生物製藥公司,專注於開發及商業化皮膚病治療方法。公司總部位於加利福尼亞州西湖村。
財務指標
營業收入
2026-09-30
$143.91M
2026-06-30
$129.86M
2026-03-31
$105.39M
2025-12-31
$129.5M
營業支出
2026-09-30
$122.02M
2026-06-30
$102.49M
2026-03-31
$104.7M
2025-12-31
$99.42M
淨利潤
2026-09-30
$8.8M
2026-06-30
$15M
2026-03-31
-$11.29M
2025-12-31
$17.39M
淨利潤率
2026-09-30
6.11%
2026-06-30
11.55%
2026-03-31
-10.71%
2025-12-31
13.43%
每股收益
2026-09-30
$0.06
2026-06-30
$0.11
2026-03-31
$-0.09
2025-12-31
$0.13
息稅折舊攤銷前利潤
2026-09-30
$12.51M
2026-06-30
$17.14M
2026-03-31
-$6.27M
2025-12-31
$21.42M
有效稅率
2026-09-30
2.16%
2026-06-30
0.89%
2026-03-31
-0.83%
2025-12-31
2.63%
項目
2026-09-30
2026-06-30
2026-03-31
2025-12-31
營業收入
$143.91M
$129.86M
$105.39M
$129.5M
營業支出
$122.02M
$102.49M
$104.7M
$99.42M
淨利潤
$8.8M
$15M
-$11.29M
$17.39M
淨利潤率
6.11%
11.55%
-10.71%
13.43%
每股收益
$0.06
$0.11
$-0.09
$0.13
息稅折舊攤銷前利潤
$12.51M
$17.14M
-$6.27M
$21.42M
有效稅率
2.16%
0.89%
-0.83%
2.63%
常見問題
ARQT is the ticker symbol for Arcutis Biotherapeutics, Inc., a biopharmaceutical company focused on developing and commercializing treatments for immune-mediated dermatological conditions. The stock represents ownership in this clinical-stage company, which is listed on the Nasdaq Global Market. Arcutis's pipeline includes topical therapies for plaque psoriasis, atopic dermatitis, and other skin diseases. Investors should note ARQT is a small-cap biotech stock, and its value is closely tied to clinical trial results and regulatory approvals.
Recent performance of ARQT stock can be found in the price chart and performance data displayed on this page. Stock performance for a biopharmaceutical company like Arcutis is often influenced by clinical trial readouts, regulatory decisions, and commercial uptake of approved products. For the latest price changes and percentage moves, refer to the live quote and historical returns section on this page.
Evaluating ARQT's valuation typically involves analyzing its market capitalization, cash position, and pipeline potential, as profitability may be limited. Biotech companies are often assessed using discounted cash flow models, comparable company analysis, or price-to-sales ratios rather than P/E. Since ARQT may not have positive earnings, traditional valuation metrics might not apply. For current valuation multiples and market cap, see the data provided on this stock page.
ARQT stock may be traded in pre-market and after-hours sessions on certain U.S. exchanges, depending on availability and your brokerage. These extended-hours trades occur outside the standard 9:30 AM to 4:00 PM Eastern Time window. However, liquidity can be lower and spreads wider, which may impact execution. Check with your broker for specific extended-hours trading policies for ARQT.
ARQT does not currently pay dividends. As a clinical-stage biopharmaceutical company, Arcutis Biotherapeutics focuses on funding research, development, and commercialization of its dermatology treatments rather than returning capital to shareholders through dividends. This is common among growth-oriented biotech firms. For the most up-to-date dividend information, refer to the dividend section on this page.
Key risks for ARQT include clinical trial failures, regulatory delays or rejections, and commercial challenges for its products. As a biotech, the company may face competition, intellectual property disputes, and the need for additional financing, which could dilute shareholders. Market sentiment and broader economic conditions can also affect ARQT's stock price. For a comprehensive risk profile, review the company's SEC filings and the risk factors disclosed in its annual report.